TABLE 1.
Demographic and Clinical Characteristics of Study Participants at Baselinea
| All BMT Recipients N = 378 |
Autologous BMT Recipients N = 178 |
Allogeneic BMT Recipients N = 200 |
Heathy Controls N = 98 |
||||
|---|---|---|---|---|---|---|---|
| Characteristic | No (%) | Pb | No. (%) | P | No. (%) | P | No. (%) |
| Mean age (range), y | 50.1 (18-73) | .51 | 52.0 (18-73) | .94 | 48.3 (19-71) | .22 | 51.1 (19-72) |
| Sex | |||||||
| Female | 151 (39.9) | .28 | 71 (39.9) | .31 | 80 (40.0) | .33 | 45 (45.9) |
| Ethnicity | |||||||
| Non-Hispanic white | 256 (67.7) | .67 | 128 (71.9) | .29 | 128 (64.0) | .83 | 64 (65.3) |
| Educational level | |||||||
| <College degree | 183 (48.4) | .06 | 85 (47.8) | .12 | 98 (49.0) | .07 | 37 (37.8) |
| Annual household income | |||||||
| <$50,000 | 102 (27.0) | 43 (24.2) | 59 (29.5) | 35 (35.7) | |||
| $50,000 to <$100,000 | 150 (39.7) | 75 (42.1) | 75 (37.5) | 30 (30.6) | |||
| ≥$100,000 | 126 (33.3) | .15 | 60 (33.7) | .07 | 66 (33.0) | .43 | 33 (33.7) |
| IQc | |||||||
| ≥50th percentile | 181 (47.9) | .006 | 93 (52.2) | .05 | 88 (44.0) | .003 | 63 (64.3) |
| Primary diagnosis | |||||||
| ALL | 35 (9.2) | 0 (0) | 35 (17.5) | ||||
| AML | 115 (30.4) | 8 (4.5) | 107 (53.5) | ||||
| HL/NHL | 138 (36.5) | 104 (58.4) | 34 (17.0) | ||||
| MM | 71 (18.8) | 66 (37.1) | 5 (2.5) | ||||
| Other | 19 (5.0) | 0 (0) | 19 (9.5) | ||||
| Conditioning irradiation | |||||||
| 111In/90Y | 28 (7.4) | 23 (12.9) | 5 (2.5) | ||||
| Myeloablative TBI | 86 (22.7) | 13 (7.3) | 73 (36.5) | ||||
| Reduced intensity TBI/TMI | 11 (2.9) | 8 (4.5) | 3 (1.5) | ||||
| Risk of disease recurrence at BMTd | |||||||
| High | 233 (61.6) | 123 (69.1) | 110 (53.4) | ||||
Abbreviations: 111In, indium-111; 90Y, yttrium-90; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BMT, blood or bone marrow transplantation; HL, Hodgkin lymphoma; IQ, intelligence quotient; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; TBI, total body irradiation; TMI, total bone marrow irradiation.
Bolded values indicate a statistical significance level of P < .05.
P values were calculated by comparing each BMT group with healthy controls using the Student t test for continuous variables and the chi-square test for categorical variables.
IQ scores were missing for 7 allogeneic BMT recipients.
Patients with the following diagnoses were considered to be at standard risk of disease recurrence at BMT: ALL, AML (except secondary AML), HL/NHL in first or second complete remission, MM in complete remission, first chronic phase of chronic myeloid leukemia, myelodysplastic syndrome (refractory anemia), myelofibrosis, or myeloproliferative disorder. All other patients were categorized as being at high risk.